These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12709032)

  • 21. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
    Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S
    Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing pattern of care of boys with haemophilia in western European centres.
    Chambost H; Ljung R;
    Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The orthopaedic status of severe haemophiliacs in Spain.
    Aznar JA; Magallón M; Querol F; Gorina E; Tusell JM
    Haemophilia; 2000 May; 6(3):170-6. PubMed ID: 10792475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalized prophylaxis.
    Collins PW
    Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing outcomes of different treatment regimens for severe haemophilia.
    van den Berg HM; Fischer K; van der Bom JG
    Haemophilia; 2003 May; 9 Suppl 1():27-31; discussion 31. PubMed ID: 12709034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. History of prophylaxis.
    Berntorp E
    Haemophilia; 2013 Mar; 19(2):163-5. PubMed ID: 23419107
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
    Petrini P
    Haemophilia; 2001 Jan; 7(1):99-102. PubMed ID: 11136389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis in real life scenarios.
    Fischer K; Konkle B; Broderick C; Kessler CM
    Haemophilia; 2014 May; 20 Suppl 4():106-13. PubMed ID: 24762285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
    Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
    Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia.
    Miners AH; Lee CA
    Haemophilia; 2004 Mar; 10 Suppl 1():58-62. PubMed ID: 14987250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-demand treatment in persons with severe haemophilia.
    Saulyte Trakymiene S; Steen Carlsson K
    Eur J Haematol Suppl; 2014 Aug; 76():39-47. PubMed ID: 24957106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness in establishing hemophilia carrier detection and prenatal diagnosis services in a developing country with limited health resources.
    Sasanakul W; Chuansumrit A; Ajjimakorn S; Krasaesub S; Sirachainan N; Chotsupakarn S; Kadegasem P; Rurgkhum S
    Southeast Asian J Trop Med Public Health; 2003 Dec; 34(4):891-8. PubMed ID: 15115107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G; Lafeber FP
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.